Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues

Molecular Psychiatry

Volumn 13, Issue 12, 2008, Pages 1118-1128

  Huang, J T J ^a   Wang, L ^a   Prabakaran, S ^a   Wengenroth, M ^a   Lockstone, H E ^a   Koethe, D ^b   Gerth, C W ^b   Gross, S ^b   Schreiber, D ^b   Lilley, K ^a   Wayland, M ^a   Oxley, D ^c   Leweke, F M ^b   Bahn, S ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF COLOGNE   (Germany)

^c BABRAHAM INSTITUTE   (United Kingdom)

Author keywords

Apolipoprotein A1; Brain; Peripheral tissues; Proteomics; Schizophrenia

Indexed keywords

APOLIPOPROTEIN A1;

ADULT; ARTICLE; BLOOD ANALYSIS; BRAIN TISSUE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE; FEMALE; HUMAN; HUMAN TISSUE; LIVER; MALE; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN EXPRESSION; PROTEOMICS; SCHIZOPHRENIA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; WESTERN BLOTTING;

ADULT; APOLIPOPROTEIN A-I; BRAIN; DOWN-REGULATION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; PROTEIN ARRAY ANALYSIS; PROTEOME; PROTEOMICS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 56449084674     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/sj.mp.4002108     Document Type: Article

References (25)

1. Jablensky A, Sartorius N, Ernberg G, Anker M, Korten A, Cooper JE et al. Schizophrenia: manifestations, incidence and course in different cultures. AWorld Health Organization ten-country study. Psychol Med Monogr Suppl 1992; 20: 1-97.
2. Owen MJ, Williams NM, O'Donovan MC. The molecular genetics of schizophrenia: new findings promise new insights. Mol Psychiatry 2004; 9: 14-27.
3. Flyckt L, Borg J, Borg K, Ansved T, Edman G, Bjerkenstedt L et al. Muscle biopsy, macro EMG, and clinical characteristics in patients with schizophrenia. Biol Psychiatry 2000; 47: 991-999.
4. Schwarz MJ, Muller N, Riedel M, Ackenheil M. The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms. Med Hypotheses 2001; 56: 483-486.
5. Haupt DW, Newcomer JW. Abnormalities in glucose regulation associated with mental illness and treatment. J Psychosom Res 2002; 53: 925-933.
6. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160: 284-289.
7. Heiskanen T, Niskanen L, Lyytikainen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003; 64: 575-579.
8. Kirkegaard C, Faber J. The role of thyroid hormones in depression. Eur J Endocrinol 1998; 138: 1-9.
9. Baumgartner A, Pietzcker A, Gaebel W. The hypothalamic-pituitary-thyroid axis in patients with schizophrenia. Schizophr Res 2000; 44: 233-243.
10. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 2004; 9: 643, 684-697.
11. Swatton JE, Prabakaran S, Karp NA, Lilley KS, Bahn S. Protein profiling of human postmortem brain using 2-dimensional fluorescence difference gel electrophoresis (2-D DIGE). Mol Psychiatry 2004; 9: 128-143.
12. Huang JT, Leweke FM, Oxley D, Wang L, Harris N, Koethe D et al. Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 2006; 3: e428.
13. Mero N, Van Tol A, Scheek LM, Van Gent T, Labeur C, Rosseneu M et al. Decreased postprandial high density lipoprotein cholesterol and apolipoproteins A-I and E in normolipidemic smoking men: relations with lipid transfer proteins and LCAT activities. J Lipid Res 1998; 39: 1493-1502.
14. Lewis GF. Determinants of plasma HDL concentrations and reverse cholesterol transport. Curr Opin Cardiol 2006; 21: 345-352.
15. Mimmack ML, Ryan M, Baba H, Navarro-Ruiz J, Iritani S, Faull RL et al. Gene expression analysis in schizophrenia: reproducible upregulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. Proc Natl Acad Sci USA 2002; 99: 4680-4685.
16. Thomas EA, Dean B, Scarr E, Copolov D, Sutcliffe JG. Differences in neuroanatomical sites of apoD elevation discriminate between schizophrenia and bipolar disorder. Mol Psychiatry 2003; 8: 167-175.
17. Yang Y, Wan C, Li H, Zhu H, La Y, Xi Z et al. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 2006; 78: 3571-3576.
18. Thomas EA, George RC, Danielson PE, Nelson PA, Warren AJ, Lo D et al. Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol Psychiatry 2003; 8: 950, 983-993.
19. Reiss AB. Cholesterol and apolipoprotein E in Alzheimer's disease. Am J Alzheimers Dis Other Demen 2005; 20: 91-96.
20. Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat Med 2004; 10(Suppl): S2-S9.
21. Bossy-Wetzel E, Talantova MV, Lee WD, Scholzke MN, Harrop A, Mathews E et al. Crosstalk between nitric oxide and zinc pathways to neuronal cell death involving mitochondrial dysfunction and p38-activated K+ channels. Neuron 2004; 41: 351-365.
22. Onyango IG, Khan SM. Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. Curr Alzheimer Res 2006; 3: 339-349.
23. Torrey EF, Yolken RH. The schizophrenia-rheumatoid arthritis connection: infectious, immune, or both? Brain Behav Immun 2001; 15: 401-410.
24. Yao JK, Thomas EA, Reddy RD, Keshavan MS. Association of plasma apolipoproteins D with RBC membrane arachidonic acid levels in schizophrenia. Schizophr Res 2005; 72: 259-266.
25. Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 2006; 3: e327.